Moscontin Lp (Morphine Sulfate)

Morphine sulfate acts as an agonist at mu‑opioid receptors in the brain and spinal cord. By activating these receptors, it reduces the release of neurotransmitters involved in pain signaling, lowers neuronal excitability, and diminishes the perception of pain, providing both analgesia and sedation.

The appropriate dose of Moscontin Lp is individualized by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and clinical condition. Dosage adjustments are made according to response and tolerability, following local prescribing guidelines for extended‑release opioids.

Moscontin Lp is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out. It should only be used if the potential benefit justifies the potential risk. Morphine is excreted in breast milk, so breastfeeding mothers should discuss alternatives with their healthcare provider.

To order Moscontin Lp, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moscontin Lp provides extended‑release delivery of morphine, offering steadier plasma concentrations over 12‑24 hours compared with immediate‑release opioids that require multiple daily doses. This can improve adherence and provide more consistent pain control, but it also requires careful dose titration and monitoring for accumulation.

Moscontin Lp should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in the original container, protect them from moisture, heat and direct sunlight, and ensure they are out of reach of children.

Moscontin Lp is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole; it must not be crushed, chewed, or split, as this can release the entire dose at once and increase the risk of serious side effects.

The most serious risks include respiratory depression, severe hypotension, opioid dependence or misuse, adrenal insufficiency, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of these events, especially during dose initiation or when combined with other depressant drugs.

Moscontin Lp is contraindicated in individuals with known hypersensitivity to morphine or any component of the formulation, in patients with untreated severe respiratory depression, and in those who have taken monoamine oxidase inhibitors within the past 14 days. Caution is also advised for patients with significant renal or hepatic impairment.